•
Dec 31, 2022
Lexicon Pharmaceuticals Q4 2022 Earnings Report
Reported financial results for Q4 2022 and provided a business update.
Key Takeaways
Lexicon Pharmaceuticals reported a net loss of $30.5 million for the fourth quarter of 2022, compared to a net loss of $25.6 million for the same period in 2021. As of December 31, 2022, Lexicon had $138.4 million in cash and investments.
NDA for Sotagliflozin on track for May 2023 PDUFA date.
LX9211 demonstrates consistent results in full data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain.
Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia.
Lexicon management to hold conference call and webcast at 5:00 pm Eastern Time.